The investigation of tumor proliferation through Ki-67 staining showed that the Ki-67 level in LD tumor was significantly lower compared with non-LD mice with same treatment (two-way ANOVA, LD: P < 0.001, immunotherapy: P < 0.001), while immunotherapy only decrease tumor proliferation in LD mice rather in non-LD mice (post hoc test: P = 0.037 for MOC1+LD+αPD-1 vs. MOC1+LD+IgG and P = 0.003 for LD+MOC1+αPD-1 vs. LD+MOC1+IgG; Fig. 5A and C), which illustrated that LD inhibited tumor proliferation of OSCC and improved the effect of immunotherapy in reduce tumor growth. This evidence concerns the gene MKI67 and neoplasm.